As another week comes to a close, it is time to take a look at the U.S. healthcare IPOs scheduled for the week ahead.
Shares of Galapagos NV (GLPG), which touched an all-time high of $174.63 in intraday trading on Monday, have gained 90 percent year-to-date. GLPG was trading around $55 when we alerted our premium subscribers to this stock on July 17, 2015.
Shares of Kodiak Sciences Inc. (KOD), which touched an all-time high of $14.45 in intraday trading on Friday (July 12, 2019) have doubled since the beginning of the year.
The IPO activity in the U.S. pharma/biotech sector has had a strong showing so far this year, with 41 listings in the first half of the year, and 25 listings in the second quarter, which is almost similar to the last year's q2 biotech IPO of 24 listings.
Shares of Adverum Biotechnologies Inc. (ADVM) touched a 2-year high of $14.96 yesterday, and are up a whopping 385 percent year-to-date. The stock was trading around $4.70 when we alerted our premium subscribers to it on January 18, 2018. (Report titled "It's All In The Genes…".
Shares of Karyopharm Therapeutics Inc. (KPTI) are up more than 127% from their 52-week low of $3.92 recorded on March 1, 2019.
The stock market is designed to transfer money from the Active to the Patient." - Warren Buffett
Shares of BridgeBio Pharma Inc. are expected to begin trading on the Nasdaq Global Select Market today (June 27, 2019), under the ticker symbol "BBIO".
Shares of CEL-SCI Corporation (CVM), which have been hitting new highs, are up over 940 percent from their 52 week low of $0.82 recorded on August 7, 2018.
As another week comes to a close, let's take a look at the biotech companies that are going public in the week ahead.
The IPO activity in the U.S. pharma/biotech sector has had a strong showing so far this year, with 32 listings till the end of May. Although the first half of June witnessed no IPO activity in the healthcare sector, the second half is going to be busy, and 5 companies are making their public debut in the week ahead.
Shares of Verrica Pharmaceuticals Inc. (VRCA) are up 12 percent year-to-date while the iShares Nasdaq Biotechnology ETF (IBB), a bellwether of investor sentiment, has gained only 8 percent for the same period.
The clinical trials can make or break drug companies as their stock price reaction
can either be overwhelmingly positive or brutal depending upon the trial results.
It has been a banner year so far for Molecular Templates Inc. (MTEM), whose shares gained a whooping 102 percent year-to-date.
IDEAYA Biosciences Inc. is an oncology-focused precision medicine company developing targeted therapeutics for patient populations selected using molecular diagnostics.